BCHT: Approval granted for clinical trial application of acellular DTP b-type influenza Haemophilus influenzae combined vaccine
I'm PortAI, I can summarize articles.
BCHT recently received approval from the National Medical Products Administration to conduct clinical trials for the acellular pertussis-diphtheria-tetanus combined vaccine against Haemophilus influenzae type b. This vaccine can prevent whooping cough, diphtheria, tetanus, and infections caused by Haemophilus influenzae type b, and is suitable for infants aged 2 months and older. If the clinical trials are successful and approved for market launch, it will help the company optimize its product structure, promote the development of its main business, and provide the public with higher quality vaccine options
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments